In light of the potential immunoregulatory impact of OBSCN expression deficiency on the TIME of BLCA, as indicated by the enrichment analysis, we initially conducted a pan-cancer investigation into the correlation between OBSCN expression and NEO, TMB, and MSI, which are emerging biomarkers associated with the efficacy of immunotherapy. The gene discussed is OBSCN; the disease is cancer.